Zusammenfassung
Dermatika zählen in Deutschland zu den verordnungsstärksten Arzneimitteln. Ihre Anwendungsgebiete sind sehr unterschiedlich. Entsprechend heterogen sind die Stoffklassen, die von den Corticosteroidexterna über die Antimykotika – sofern präferenziell zur Behandlung von Dermato- bzw. Onychomykosen zugelassen – sowie die Wundbehandlungsmittel bis zu den Hautschutz- und Pflegemitteln reichen (Abbildung 22.1). Antimykotika mit anderen Indikationen finden sich in Kapitel 9 (Antibiotika und Chemotherapeutika), Kapitel 26 (Gynä-kologika) sowie in Kapitel 34 (Mund- und Rachentherapeutika).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ågren MS, Ostenfeld U, Kallehave F, Gong Y, Raffn K, Crawford ME, Kiss K, Friis-Møller A, Gluud C, Jorgensen LN (2006): A randomized, double-blind, placebo-controlled multicenter trial evaluating topical zinc oxide for acute open wounds following pilonidal disease excision. Wound Repair Regen 4: 526-535.
Alston SJ, Cohen BA, Braun M (2003): Persistent and recurrent tinea corporis in children treated with combination antifungal/corticosteroid agents. Pediatrics 111: 201–203.
Altmeyer PJ, Matthes U, Pawlak F, Hoffmann K, Frosch PJ, Ruppert P et al. (1994): Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 30: 977–981.
Ammon HPT, Sabieraj J, Kaul R (1996): Kamille. Mechanismus der antiphlogisti-schen Wirkung von Kamillenextrakten und -inhaltsstoffen. Dtsch Apoth Ztg 136: 1821–1834.
Andrews MG, Burns M (2008): Common tinea infections in children. Am Fam Physician 77: 1415-1420.
Anonymus (2002): New treatments for actinic keratoses. Medical Letter 44: 57–58.
Antille C, Saurat JH, Lübbe J (2004): Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment. Arch Dermatol 140: 457-460.
Arican O, Sasmaz S, Ozbulu O (2006): Increased suicidal tendency in a case of psoriasis vulgaris under acitretin treatment. J Eur Acad Dermatol Venerol 20: 464-465.
Arzneimittelkommission der deutschen Ärzteschaft (1999): Nutzen und Risiken durch Fumarsäure-Ester bei der Therapie der Psoriasis. Dtsch Ärztebl 96: A-721.
Arzneimittelkommission der deutschen Ärzteschaft (2005a): Myopathie nach Tacrolimus-Salbe (Protopic®). Dtsch Ärztebl 102: A3138.
Arzneimittelkommission der deutschen Ärzteschaft (2005b): Allergisches Kontaktekzem unter Bufexamac. Dtsch Ärztebl 102: A3285.
Arzneimittelkommsission der deutsche Ärzteschaft (2006) Psychiatrische Reaktionen nach Terninafin (Lamisil®). Dtsch Ärztebl 103: A3432.
Aschoff R, Wozel G, Meurer M (2003): Aktuelle Aspekte der topischen Psoriasisbehandlung. Hautarzt 54: 237–241.
Azoulay L, Blais L, Koren G, LeLorier J, Bérard A (2008): Isotretinoin and the risk of depression in patients with acne vulgaris: a case-crossover-study. J Clin Psychiatry 69: 526-532.
Baran R, Kaoukhov A (2005): Topical antifungal drugs fort he treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venerol 19: 21–29.
Baran R, Hay RJ, Garduno JI (2008a): Review of antifungal therapy and the severity index for assessing onychomycosis: part I. J Dermatolog Treat 19: 72-81.
Baran R, Hay RJ, Garduno JI (2008b): Review of antifungal therapy, part II: treatment rationale, including specific patient populations. J Dermatolog Treat 19: 168-175.
Bell-Syer SEM, Hart R, Crawford F, Torgerson DJ, Tyrell W, Russell I (2006): Oral treatments for fungal infections of the skin of the foot (Cochrane Review). In: The Cochrane Library, Issue 1 2006. Oxford: Update Software.
Bergin SM, Wraight P (2006): Silver based dressings and topical agents for treating diabetic foot ulcers. Cochrane Darabase Syst Rev 2008 Jan 25:CD005082.
Berth-Jones J, Damstra RJ, Golsch S, Livden JK, Van Hooteghem O, Allegra F, Parker CA,; Multinational Study Group (2003): Twice weekly fluticasone propionate added to emollient maintenance treatment to reduce risk of relapse in atopic dermatitis: randomised, double-blind, parallel group study. Brit Med J 326: 1367–1373.
Biro K, Thaci D, Ochsendorf FR, Kaufmann R, Boehncke W-H (2003): Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. Contact Dermatitis 49: 80–84.
Boguniewicz M, Leung DY (2010): Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 125: 4-13.
Bradley M, Cullum N, Sheldon T (1999): The debridement of chronic wounds: a systematic review. Health Technol Assess 3: 1–78.
Braun-Falco O, Plewig G, Wolff HH, Burgdorf WHC, Landthaler M (2005): Dermato-logie und Venerologie, 5. Auflage. Springer Medizin Verlag, Heidelberg.
Bristow IR, Baran R (2006): Topical and oral combination therapy for toenail onycho-mycosis. An updated review. J Am Podiatr Med Associat 96: 116–119.
Buys LM (2007): Treatment options for atopic dermatitis. Am Fam Physician 75: 523–528.
Calow T, Oberle K, Bruckner-Tuderman L, Jakob T, Schumann H (2009): Contact dermatitis due to use of Octenisept(R) in wound care. J Dtsch Dermatol Ges 7: 759–765.
Casciano J, Amaya K, Doyle J, Arikian S, Shear N, Haspel M, Kahler K (2003): Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails. Manag Care 12: 47–54.
Christiansen B (1988): Untersuchungen über die Wirksamkeit eines Hautdesinfektionsmittels mit kationenaktivem Zusatz. Zbl Bakt Hyg B 186:368-374.
Conde JF, Yelverton CB, Balkrishnan R, Fleischer AB Jr, Feldman SR (2007): Managing rosacea: a review of the use of metronidazole alone and in combination with oral antibiotics. J Drugs Dermatol 6: 495-498.
Crawford F, Young P, Godfrey C, Bell-Syer SEM, Hart R, Brunt E, Russel I (2002): Oral treatments for toenail onychomycosis. Arch Dermatol 138: 811–816.
Crawford F, Hollis S (2007): Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev 2007 Jul 18 (3): CD001434.
Darkes MJM, Scott LJ, Goa KL (2003): Terbinafine. A review of its use in onychomycosis in adults. Am J Clin Dermatol 4: 39–65.
Daschner F (1987): Sind Lokalantibiotika bei Hautinfektionen sinnvoll? Arzneiverordnung 4: 41–46.
De Gannes GC, Ghoreishi M, Pope J, Russell A, Bell D, Adams S, Shojania K, Martinka M, Dutz JP (2007): Psoriasis and pustular dermatitis triggered by TNF-α inhibitors in patients with rheumatologic conditions. Arch Dermatol 143: 223–231.
Deutsche Dermatologische Gesellschaft (1998): Akne und ihre Subtypen. Leitlinien der Deutschen Dermatologischen Gesellschaft. AWMF-Leitlinien-Register Nr. 013/017, http://leitlinien.net.
Deutsche Dermatologische Gesellschaft (2009a): Topische Dermatotherapie mit Glukokortikoiden – Therapeutischer Index. AWMF-Leitlinien-Register Nr. 013/034, http://leitlinien.net.
Deutsche Dermatologische Gesellschaft (2009b): Therapie der Psoriasis vulgaris. Leitlinien der Deutschen Dermatologischen Gesellschaft. AWMF-Leitlinien-Register Nr. 013/001, http://leitlinien.net.
Deutsche Dermatologische Gesellschaft und Berufsverband Deutscher Dermatologen (2009): Therapie des atopischen Ekzems mit Calcimeurin-Inhibitoren. AWMF-Leitlinien-Register Nr. 013/037, http://leitlinien.net.
Deutsche Dermatologische Gesellschaft und Deutschsprachige Mykologische Gesellschaft (2008): Tinea der freien Haut. AWMF-Leitlinien-Register Nr. 013-002. http://leitlinien.net/
Deutsche Dermatologische Gesellschaft, Deutschsprachige Mykologische Gesellschaft und Berufsverband der Deutschen Dermatologen (2005): Candidose der Haut. AWMF-Leitlinien-Register Nr. 013/005, http://leitlinien.net.
Deutsche Dermatologische Gesellschaft, Deutschsprachige Mykologische Gesellschaft und Berufsverband der Deutschen Dermatologen (2006): Onychomykose. AWMF-Leitlinien-Register Nr. 013/003, http://leitlinien.net.
Deutsche Dermatologische Gesellschaft, Österreichische Gesellschaft für Dermatologie und Venerologie, Arbeitskreis Pharmaökonomie in der Dermatologie et al. (2008): Neurodermitis, AWMF-Leitlinien-Register Nr. 013/027, http://leitlinien.net.
Dinnendahl V, Fricke U (Hrsg.) (2010): Arzneistoff-Profile, Basisinformation über arzneilich wirksame Wirkstoffe. Stammlieferung 1982 mit 1. bis 23. Erg.-Lieferung 2010, Govi-Verlag Pharmazeutischer Verlag GmbH, Eschborn.
Dobie D, Gray J (2004): Fusidic acid resistance in Staphylococcus aureus. Arch Dis Child 89: 74-77.
Ebner F, Heller A, Rippke F, Tausch I (2002): Topical use of dexpanthenol in skin disorders. Am J Clin Dermatol 3: 427–433.
Eifler-Bollen R, Fluhr JW (2005): Antimikrobiell wirksame Magistralrezepturen. Stellenwert in der Praxis und kritische Anmerkungen. Hautarzt 56: 752–758.
Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RA, De Prost Y et al. (2003): International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 148 (Suppl 63): 3–10.
El Sayed F, Ammoury A, Dhaybi R, Bazex J (2006): Rosaceiform eruption to pimecro-limus. J Am Acad Dermatol 54: 548–550.
Erbagci Z (2004): Topical therapy for dermatophytoses. Should corticosteroids be included? Am J Clin Dermatol 5: 375–384.
European Medicines Agency (EMA) (2006): European Medicines Agency recommends cautious use of Protopic/Protopy and Elidel. http://www.emea.europa.eu/ pdfs/general/direct/pr/9888206en.pdf
European Medicines Agency (EMA) (2009): Raptiva (efalizumab) – Withdrawal of the marketing authorisation in the European Union. http://www.emea.europa.eu/humandocs/PDFs/EPAR/raptiva/48710709en.pdf
Falagas ME, Angelousi AG, Peppas G (2006): Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. J Am Acad Dermatol 55: 537–538.
Fiorentino DF (2007): The yin and yang of TNF-α inhibition. Arch Dermatol 143: 233–236.
Fleischer AB jr, Abramovits W, Breneman D, Jaracz E; US/Canada tacrolimus ointment study group (2007): Tacrolimus ointment is more effective than pimecrolimus cream in adult patients with moderate to very severe atopic dermatitis. J Dermatol Treat 18: 151-157.
Fleischer AB, Feldman SR (1999): Prescription of high-potency corticosteroid agents and clotrimazole-betamethasone dipropionate by pediatricians. Clin Ther 10: 1725–1731.
Fölster-Holst R, Latussek E (2007): Synthetic tannins in dermatology--a therapeutic option in a variety of pediatric dermatoses. Pediatr Dermatol 24: 296-301.
Friese K, Neumann G, Siebert J (2003): Topical antiseptics as an alternative in the treatment of acute vulvovaginal candidosis. Arch Gynecol Obstet 268: 194-197.
Fuchslochner M, Rzany B (2002): Orale anticholinerge Therapie der fokalen Hyperhidrose mit Methantheliniumbromid (Vagantin®). Hautarzt 53: 151-152.
Gemeinsamer Bundesausschuss (2010): Richtlinie des Gemeinsamen Bundesausschusses über die Verordnung von Arzneimitteln in der vertragsärztlichen Versorgung (Arzneimittel-Richtlinie/AM-RL) in der Fassung vom 18. Dezember 2008/22. Januar 2009, veröffentlicht im Bundesanzeiger 2009, Nr. 49a, zuletzt geändert am 17. Dezember 2009, veröffentlicht im Bundesanzeiger 2010 Nr. 39: S. 996, in Kraft getreten am 12. März 2010.http://www.g-ba.de/downloads/62-492-420/AM-RL-2009-12-17_3.pdf.
George A, Rubin G (2003): A systematic review and mety-analysis of treatments for impetigo. Br J Gen Pract 53: 480–487.
Geria AN, Schwartz RA (2010): Impetigo update: new challenges in the era of methicillin resistance. Cutis 85: 65-70.
Gibbs S, Harvey I (2006): Topical treatments for cutaneous warts. Cochrane Database of Systematic Reviews 2006, Issue 3. Art. No.: CD001781. DOI: 10.1002/14651858. CD001781.pub2.
Gloor M (1982): Pharmakologie dermatologischer Externa. Springer-Verlag, Berlin Heidelberg New York.
Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J (2002): Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 205: 46–53.
Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D (2003): Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 49 (1 Suppl): S1–S37.
González U, Seaton T, Bergus G, Jacobson J, Martínez-Monzón C.(2007): Systemic antifungal therapy for tinea capitis in children. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004685.
Gorman CR, White SW (2005): Rosaceiform dermatitis as a complication of treatment of facial seborrhoic dermattis with 1% pimecrolimus cream. Arch Dermatol 141: 1168.
Goulden V (2003): Guidelines for the management of acne vulgaris in adolescents. Paediatr. Drugs 5: 301–313.
Griffiths CE, Barker JN (2007): Pathogenesis and clinical features of psoriasis. Lancet 370: 263-271.
Griffiths CE, Finlay AY, Fleming CJ, Barker JN, Mizzi F, Arsonnaud S (2006): A randomized, investigator-masked clinical evaluation of the efficacy and safety of clobetasol propionate 0.05% shampoo and tar blend 1% shampoo in the treatment of moderate to severe scalp psoriasis. J Dermatolog Treat 17: 90-95.
Guenther LC (2004): Fixed-dose combination therapy for psoriasis. Am J Clin Dermatol 5: 71–77.
Gupta AK (2002): Treatment of dermatophyte toenail onychomycosis in the United States. A pharmacoeconomic analysis. J Am Pediatr Med Assoc 92: 272–286.
Gupta AK, Cherman AM, Tyring SK (2005): Viral and nonviral uses of imiquimod: A review. J Cut Med Surg 8: 338–352.
Gupta AK, Cooper EA (2008): Update in antifungal therapy of dermatophytosis. Mykopathologia 166: 353-367.
Gupta AK, Cooper EA, Ryder JE, Nicol KA, Chow M, Chaudhry MM (2004): Optimal management of fungal infections of the skin, hair, and nails. Am J Clin Dermatol 5: 225–237.
Gupta AK, Skinner AR (2003): Ciclopirox fort he treatment of superficial fungal infections: a review. Int J Dermatol 42 (Suppl 1): 3–9.
Guttman-Yassky E, Hayek T, Muchnik L, Bergman R (2003): Acute rhabdomyolysis and myoglobinuria associated with isotretinoin treatment. Int J Dermatol 42: 499-500
Hadley G, Derry S, Moore RA (2006): Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 126: 1251–1255.
Hahn C, Röseler S, Fritzsche R, Schneider R, Merk HF (1993): Allergic contact reaction to dexpanthenol: lymphocyte transformation test and evidence for microso-mal-dependent metabolism of the allergen. Contact Dermatitis 28: 81–83.
Haider A, Shaw JC (2004): Treatment of acne vulgaris. JAMA 292: 726–735.
Haugh M, Helou S, Boissel J P, Cribier BJ (2002): Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol 147: 118–121.
Hauschild A, Kähler KC, Egberts F (2006): Moderne Behandlungsoptionen bei aktini-schen Keratosen der Haut. Dtsch Med Wochenschr 131: 447–452.
Harper JC (2008): Tailoring individualized treatment plans fpr acne. Cutis 81 (1 Suppl): 23-25.
Hengge UR, Ruzicka T, Schartz RA, Cork MJ (2006): Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 54: 1–15.
Hoare C, Li Wan Po A, Williams H (2000): Systematic review of treatments for atopic eczema. Health Technol Assess 4: 1–191.
Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN (2003): Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 149: 363–369.
Hoffmann R, Happle R (2000): Current understanding of androgenetic alopecia. Part II: clinical aspects and treatment. Eur J Dermatol 10: 410–417.
Hornstein O P, Nürnberg E (Hrsg) (1985): Externe Therapie von Hautkrankheiten. Pharmazeutische und medizinische Praxis. Georg Thieme Verlag, Stuttgart New York.
Hund M, Sinkgraven R, Rzany B (2004) Randomisierte, plazebokontrollierte klinische Doppelblindstudie zur Wirksamkeit und Verträglichkeit der oralen Therapie mit Methantheliniumbromid (Vagantin®) bei fokaler Hyperhidrose. J Dtsch Dermatol Ges 2: 343-349.
Jarvis B, Figgitt DP (2003): Topical 3% diclofenac in 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol 4: 203–213.
Johnson MR, Hageboutros A, Wang K, High L, Smith JB, Diasio RB (1999): Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil. Clin Cancer Res 5: 2006–2011.
Kaymak Y (2008): Creatine phosphokinase values during isotretinoin treatment for acne. Int J Dermatol 47: 398-401.
Knapp U (1995): Grundlagen der Wundheilung und Wundbehandlung. Med Monatsschr Pharm 18: 219–230.
Koning S, Verhagen A P, Suijlekom-Smit LWA, Morris A, Butler CC, Wouden JC (2006): Interventions for impetigo (Cochrane Review). In: The Cochrane Library, 2006 Issue 2. The Cochrane Collaboration, John Wiley & Sons, Ltd.
Koo JYM (2005): New developments in topical sequential therapy for psoriasis. Skin Therapy Lett 10: 1–4.
Korting HC (1995): Dermatotherapie: ein Leitfaden. Springer-Verlag, Berlin Heidelberg New York.
Korting HC, Schäfer-Korting M., Klövekorn W., Klövekorn G., Martin C., Laux P. (1995): Comparative efficacy of hamamelis distillate and hydrocortisone cream in atopic eczema. Eur J Clin Pharmacol 48: 461–465.
Korting HC, Schöllmann C (2009): Management der Acne vulgaris: Fokus auf Clin-damycin und Zink. Hautarzt 60: 42-47.
Krawtchenko N, Roewert-Huber J, Ulrich M, Mann I, Sterry W, Stockfleth E (2007): A randomised study of topical 6% imiquimod vs. Topical 5-fluorouracil vs. Cryosur-gery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-up. Br J Dermatol 157 (Suppl 2): 34-40.
Kujath P, Michelsen A (2008): Wunden – von der Physiologie zum Verband. Dtsch Ärztebl 105: 239-248.
Landau M, Mesterman R, Ophir J, Mevorah B, Alcalay J, Harel A, Nevo Y (2001): Clinical significance of markedly elevated serum creatine kinase levels in patients with acne on isotretinoin. Acta Derm Venereol 81: 350-352.
Langer A, Rogowski W (2009): Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Services Research 2009, 9:115 (doi:10.1186/1472-6963 -9-115)
Lansdown AB (2004): A review of the use of silver in wound care: facts and fallacies. Br J Nurs 13 (6 Suppl): S6–S19.
Lansdown AB, Mirastschijski U, Stubbs N, Scanlon E, Ågren MS (2007): Zinc in wound healing: theoretical, experimental, and clinical aspects. Wound Repair Regen 15: 2-16.
Lebwohl M (1999): The role of salicylic acid in the treatment of psoriasis. Int J Der-matol 38: 16–24.
Lecha M, Effendy I, Feuilhade de Chauvin M, Di Chiacchio N, Baran R (2005): Treatment options – development of consensus guidelines. J Eur Acad Dermatol Venereol 19 (Suppl 1): 25–33.
Lee S, Selva D, Huilgol SC, Goldberg RA, Leibovitch I (2007): Pharmacological treatments for basal cell carcinoma. Drugs 67: 915–934.
Leung DYM (2001): Atopic dermatitis and the immune system: The role of superantigens and bacteria. J Am Acad Dermatol 45: S13–S16.
Lohde H, Stahlmann R (Hrsg.) (2004): Nadifloxacin – irrationaler Einsatz eines Flu-orchinolons zur lokalen Aknetherapie. Zeitschr Chemother 25: 27–29.
Løkkevik E, Skovlund E, Reitan JB, Hannisdal E, Tanum G (1996): Skin treatment with Bepanthen cream versus no cream during radiotherapy. Acta Oncol 35: 1021–1026.
Lunan HN (1975): Topical treatment of the burn patient. Am J Hosp Pharm 32: 599–605.
Maiche AG, Gröhn P, Mäki-Hokkonen H (1991): Effect of chamomile cream and almond ointment on acute radiation skin reaction. Acta Oncol 30: 395–396.
Marqueling AL, Zane LT (2007): Depression and suicidal behavior in acne patients treated with isotretinoin: a systematic review. Semin Cutan Med Surg 26: 210-220.
Mason J, Mason AR, Cork MJ (2002): Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 146: 351–364.
Mayser P, Hensel J, Thoma W, Podobinska M, Geiger M, Ulbricht H Haak T (2004): Prevalence of fungal foot infections in patients with diabetes mellitus type 1 – underestimation of moccasin-type tinea. Exp Clin Endocrinol Diabetes 112: 264–268.
McClellan KJ, Noble S (2000): Topical metronidazole. A review of its use in rosacea. Am J Clin Dermatol 1: 191–199.
McIntyre WJ, Downs MR, Bedwell SA (2007): Treatment options for actinic keratoses. Am Fam Physician 76: 667-671.
Menezes de Padua CA, Schnuch A, Nink K, Pfahlberg A, Uter W (2008): Allergic contact dermatitis to topical drugs – epidemiological risk assessment. Pharmaco-epidemiol Drug Saf 2008 Mar 26, Epub ahead of print.
Merk HF (2007): Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol 46: 12–18.
Möhrenschlager M, Seidl HP, Ring J, Abeck D (2005): Pediatric tinea capitis. Recognition and management. Am J Clin Dermatol 6: 203–213.
Mrowietz U, Rostami-Yazdi M, Neureither M, Reich K (2009): 15 Jahre Fumaderm: Fumarsäureester für die systemische Behandlung der mittelschweren und schweren Psoriasis vulgaris. JDDG 7 (Suppl 2): S3-S16.
Müller G, Kramer A (2008) Biocompatibility index of antiseptic agents by parallel assessment of antimicrobial activity and cellular cytotoxicity. Antimicrob Chemother 61: 1281–1287.
Muller A, Talon D, Potier A, Belle E, Cappelier G, Bertrand X (2005): Use of intranasal mupirocin to prevent methicillin-resistant Staphylococcus aureus infection in intensive care units. Critical Care 9: R246–R250.
Mutschler E, Geisslinger G, Kroemer HK, Ruth P, Schäfer-Korting M (2008): Mutschler Arzneimittelwirkungen, Lehrbuch der Pharmakologie und Toxikologie, 9. Auflage. Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart.
Naldi L, Griffiths CEM (2005): Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 152: 597–615.
Niedner R (1998): Kortikoide in der Dermatologie. UNI-MED Verlag, Bremen.
Niedner R, Ziegenmeyer J (Hrsg) (1992): Dermatika. Therapeutischer Einsatz, Pharmakologie und Pharmazie. Wissenschaftliche Verlagsgesellschaft, Stuttgart.
Opstelten W, Neven AK, Eekhof J (2008): Treatment and prevention of herpes labialis. Can Fam Physician 54: 1683-1687.
Oranje A P, Chosidow O, Sacchidanand S, Todd G, Singh K, Scangarella N, Shawar R, Twynholm M; TOC100224 Study Team (2007): Topical retapamulin ointment, 1%, versus sodium fusidate ointment, 2%, for impetigo: a randomized, observer-blinded, noninferiority study. Dermatology 215: 331-340.
Palfreyman S, Nelson EA, Michaels JA (2007): Dressings for venous leg ulcers: systematic review and mety-analysis. Br Med J 335: 244-248.
Paller AS, Lebwohl M, Fleischer AB jr, Antaya R, Langley RG, Kirsner RS, Blum RR, Rico MJ, Jaracz E, Crowe A, Linowski GJ; US/Canada Tacrolimus Ointment Study Group (2005): Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: results from 3 randomized, comparative studies. J Am Acad Dermatol 52: 810-822.
Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, Van Voorhees AS, Young M, Rittenberg S, Lebwohl MG, Horn EJ, for the Psoriasis Foundation (2007): National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 143: 239–242.
Patel B, Siskin S, Krazmien R, Lebwohl M (1998): Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 38: 1010–1011.
Peserico A, Städtler G, Sebastian M, Fernandez RS, Vick K, Bieber T (2008): Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br J Dermatol 158:801,807.
Petersen EE, Doerr H W, Gross G, Petzoldt D, Weissenbacher ER, Wutzler P (1999): Der Herpes genitalis. Dtsch Ärztebl 96: A-2358–A2364.
Post B, Jänner M (1971): Zur Indikation der Gerbstofftherapie in der Dermatologie. Klinische Erfahrungen mit Tannosynt. Ther Ggw 110: 1477–1494.
Qureshi AA, Fischer MA (2006): Topical calcineurin inhibitors for atopic dermatitis – Balancing clinical benefit and possible risks. Arch Dermatol 142: 633–637.
Raborn G W, McGaw W T, Grace M, Eng P, Percy J, Samuels S (1989): Herpes labialis treatment with acyclovir 5% modified aqueous cream: A double-blind, randomized trial. Oral Surg. Oral Med Oral Pathol Oral Radiol Endod 67: 676–679.
Rigopoulos D, Rallis E, Gregoriou S, Larios G, Belyayeva Y, Gkouvi K, Katsambas A (2009): Treatment of Pseudomonas nail infections with 0.1% octenidine dihydro-chloride solution. Dermatology 218: 67–68.
Ring J, Fröhlich HH (1985): Wirkstoffe in der dermatologischen Therapie, 2. Aufl, Springer-Verlag, Berlin Heidelberg.
Roberts DT, Taylor WD, Boyle J (2003): Guidelines for treatment of onychomycosis. Br J Dermatol 148: 402–410.
Ruzicka T (2006): Methylprednisolone aceponate in eczema and other inflammatory skin disorders – a clinical update. Int J Clin Pract 60: 85–92.
Sapijaszko MJA (2005): Imiquimod 5% cream (Aldara®) in the treatment of basal cell carcinoma. Skin Ther Lett 10: 2–5.
Schäfer-Korting M, Schmid MH, Korting HC (1996): Topical glucocorticoids with improved risk-benefit ratio. Drug Safety 14: 375–385.
Schlievert PM, Strandberg KL, Lin YC, Peterson ML, Leung DY (2010): Secreted virulence factor comparison between methicillin-resistant and methicillin-sensitive Staphylococcus aureus, and its relevance to atopic dermatitis. J Allergy Clin Immunol 125: 39-49.
Schmitt J, Meurer M (2006): Topische Kombinationstherapien bei Psoriasis. Stellenwert von Calcitriol und Vitamin-D-Analoga. Hautarzt 57: 679–684.
Schneider LA, Hinrichs R, Scharfetter-Kochanek K (2007): Indikationen zur UVB-Phototherapie. Dtsch Med Wochenschr 132: 888–891.
Schnuch A, Gefeller O, Uter W (2005): Eine heimtückische und häufige Nebenwirkung: Kontaktallergien durch das Ekzemtherapeutikum Bufexamac. Ergebnisse des IVDK. Dtsch Med Wochenschr 130: 2881–2886.
Schnuch A, Szliska C, Uter W (2009): Allergisches Gesichtsekzem. Auswertungen des IVDK und Literaturübersicht. Hautarzt 60: 13-21.
Schülke & Mayr GmbH (2008): Wichtige Information zur Arzneimittelsicherheit von Octenisept® (Octenidinhydrochlorid, Phenoxyethanol) – Oedematöse Schwellungen und Gewebeschädigungen nach Einbringen unter Druck in Stichwunden bei handchirurgischen Eingriffe. Rote Hand Brief 13. Februar 2008, http://www.akdae.de/20/40/20080213.pdf.
Schulze-Dirks A, Frosch PJ (1988): Kontaktallergie auf Dexpanthenol. Hautarzt 39: 375–377.
Sibbald RG, Orsted H, Schultz GS, Coutts P, Keast D, International Wound Bed Preparation Advisory Board, Canadian Chronic Wound Advisory Board (2003): Preparing the wound bed 2003: focus on infection and inflammation. Ostomy Wound Manage 49: 23–51.
Sigurgeirsson B, Elewski BE, Rich PA, Opper C, Cai B, Nyirady J, Bakshi R (2006): Intermittent versus continuous terbinafine in the treatment of toenail onychomycosis: A randomaized, double-blind comparison. J Dermatol Treatm 17: 38–44.
Singer AJ, Dagum AB (2008): Current management of acute cutaneous wounds. N Engl J Med 359: 1037-1046.
Smith RG (2008): Enzymatic debriding agents: an evaluation of the medical literature. Ostomy Wound Manage 54: 16-34.
Solares CA, Batra PS, Hall GS, Citardi MJ (2006): Treatment of chronic rhinosinusitis exacerbations due to methicillin-resistant Staphylococcus aureus with mupirocin irrigations. Am J Otolaryngol 27: 161–165.
Spruance SI, Kriesel JD (2002): Treatment of herpes simplex labialis. Herpes 9: 64–69.
Stille W, Brodt HR, Groll AH, Just-Nübling G (2005): Antibiotika-Therapie. Klinik und Praxis der antiinfektiösen Behandlung, 11. Auflage. Schattauer, Stuttgart-New York.
Storm-Versloot MN, Vos CG, Ubbink DT, Vermeulen H (2010): Topical silver for preventing wound infection. Cochrane Database Syst Rev 2010 Mar 17;3:CD006478.
Strömberg HE, Ågren MS (1984): Topical zinc oxide treatment improves arterial and venous leg ulcers. Br J Dermatol 111: 461–468.
Sunderkötter C, Herrmann M, Jappe U (2006): Antimikrobielle Therapie in der Dermatologie. J Dtsch Dermatol Ges 4: 10–26.
Sweetman SC (ed) (2009): Martindale 36: The Complete Drug Reference, 36th ed, Pharmaceutical Press, London.
Tadicherla S, Ross K, Shenefelt PD, Fenske NA (2009): Topical corticosteroids in dermatology. J Drugs Dermatol 8: 1093-1105.
Tan H-H (2004): Topical antibacterial treatments for acne vulgaris. Comparative review and guide to selection. Am J Clin Dermatol 5: 79–84.
Thaçi D, Schöfer H (2005): Topische Antibiotika zur Therapie von Hautinfektionen. Hautarzt 56: 381–396.
Thiboutot DM (2008 a): Overview of acne and its treatment. Cutis 81 (1 Suppl): 3-7.
Thiboutot DM (2008 b): Versatility of azelaic acid 15% gel in treatment of inflammatory acne vulgaris. J Drugs Dermatol 7: 13-16.
Thielitz A, Gollnick H (2008): Topical retinoids in acne vulgaris: update on efficacy and safety. Am J Clin Dermatol 9: 369-381.
Thielitz A, Kratheim A, Gollnick H (2006): Update in retinoid therapy of acne. Dermatol Ther 19: 272–279.
Tredget EE, Shankowsky HA, Groeneveld A, Burrell R (1998): A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil 19: 531–537.
Ubriani R, Van Voorhees AS (2007): Onset of psoriasis during treatment with TNF-α antagonists: a report of 3 cases. Arch dermatol 143: 270–272.
U.S. Food and Drug Adminstration (2005): Elidel (pimecrolimus) Cream and Pro-topic (tacrolimus) Ointment. http://www.fda.gov/cder/drug/advisory/elidel_pro-topic.htm.
Uter W, Geier J, Fuchs T (2000): Contact allergy to polidocanol, 1992 to 1999. J All Clin Immunol 106: 1203–1204.
van de Kerkhof (2006): Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol 20: 639–650.
van Zuuren EJ, Gupta AK, Gover MD, Graber M, Hollis S (2007): Systematic review of rosacea treatments. J Am Acad Dermatol 56: 107-1015.
von Krogh G (1978): Topical treatment of penile condylomata acuminata with podophyllin, podophyllotoxin and colchicine. A comparative study. Acta Derm Venereol 58: 163-168.
von Krogh G, Longstaff E (2001): Podophyllin office therapy against condyloma should be abandoned. Sex Transm Inf 77: 409-412.
Walluf-Blume D (1991): Aufbereitung und Nachzulassung von OTC-Arzneimitteln in den USA 1990. Pharm Ind 53: 152–158.
Wananukul S, Limpongsanuruk W, Singalavanija S, Wisuthsarewong W (2006): Comparison of dexpanthenol and zinc oxide ointment with ointment base in the treatment of irritant diaper dermatitis from diarrhea: a multicenter study. J Med Assoc Thai 89: 1654-1658.
Warnecke J, Wendt A (1998): Anti-inflammatory action of pale sulfonated shale oile (ICHTHYOL pale) in UVB erythema test. Inflamm Res 47: 75–78.
Warshaw EM, Fett DD, Bloomfield HE, Grill J P, Nelson DB, Quintero V, Carver SM, Zielke GR, Lederle FA (2005): Pulse versus continuous terbinafine for onycho-mycosis: a randomized, double-blind, controlled study. J Am Acad Dermatol 53: 578–584.
Wickline MM (2004): Prevention and treatment of acute radiation dermatitis: a literature review. Oncol Nurs Forum 31: 237-247.
Wilkinson JD (1998): Fusidic acid in dermatology. Br J Dermatol 139 (Suppl 53): 37–40.
Williams H (2002): New treatments for topic dermatitis. Brit Med J 324: 1533–1534.
Wohlrab J (2006): Basistherapie der Psoriasis vulgaris. Hautarzt 57: 661–665.
Wolff HH, Kieser M (2007): Hamamelis in children with skin disorders and skin injuries: results of an observational study. Eur J Pediatr 166: 943-948.
Worret WI, Fluhr JW (2006): Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. J Dtsch Dermatol Ges 4: 293–300.
Wright JB, Lam K, Burrell RE (1998): Wound management in an era of increasing bacterial antibiotic resistance: A role for topical silver treatment. Am J Infect Control 26: 572–577.
Yan J, Chen SL, Wang HN, Wu TX (2006): Meta-analysis of 5% imiquimod amd 0,5% podophyllotoxin in the treatment of condylomata acuminata. Dermatology 213: 218-223.
Yan J, Chen SL, Wang HN, Zhou W, Wang FS (2008): Meta-analysis of tacrolimus ointment for atopic dermatitis in pediatric patients. Pediatr Dermatol 25: 117-120.
Zaenglein AL, Thiboutot DM (2006): Expert Committee recommendations for acne managemant. Pediatrics 118: 1188–1199.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Fricke, U. (2010). Dermatika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2010. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13380-0_22
Download citation
DOI: https://doi.org/10.1007/978-3-642-13380-0_22
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13379-4
Online ISBN: 978-3-642-13380-0
eBook Packages: Medicine (German Language)